HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Allergy & Immunology
Cohort
Efgartigimod improved MG-ADL and QMG scores in 81 Chinese patients with generalized myasthenia gravis.
Many Myasthenia Gravis Patients Need Just One Treatment Cycle
This single-center, retrospective analysis evaluated efgartigimod in 81 Chinese patients with generalized myasthenia gravis. At week 4, 65 p…
Most patients with myasthenia gravis controlled symptoms after a single treatment cycle, with fewer infusions possible for some.
Frontiers
Apr 27, 2026
Psychiatry
Cohort
Sequential efgartigimod and rituximab induced improvement in three patients with refractory autoimmune encephalitis
Sequential efgartigimod and rituximab showed improvement in three patients with autoimmune encephalitis
This case series describes three patients with refractory autoimmune encephalitis treated with sequential efgartigimod and rituximab. All th…
Three patients with difficult autoimmune encephalitis improved after sequential treatment, suggesting a potential new option for those who d…
Frontiers
Apr 24, 2026
Drug Pipeline
RCT
Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis.
New Hope for All Myasthenia Gravis Patients
This post hoc, sex-specific subgroup analysis of the ADAPT Phase 3 RCT evaluated efgartigimod in 86 females and 43 males with AChR-Ab+ gener…
A new treatment for myasthenia gravis works equally well for women and men, offering the same relief from severe muscle weakness regardless …
Apr 18, 2026
Diabetes & Endocrinology
Cohort
Efgartigimod showed higher independent walking at week 4 and running at week 12 versus IVIG in GBS patients unable to walk.
A Newer Drug Outperformed the Standard Treatment for a Paralyzing Nerve Disease
This single-center retrospective study evaluated efgartigimod versus intravenous immunoglobulin (IVIG) in 34 Guillain-Barré syndrome patient…
A newer drug helped 100% of paralyzed Guillain-Barré patients walk again in four weeks, outperforming the standard treatment in a recent stu…
Frontiers
Apr 18, 2026
Oncology
Meta-analysis
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …
Apr 14, 2026